Stille AB
Stille AB develops, manufactures, and distributes medtech products in Sweden and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut, eye, blepharoplasty, operating, vascular, tenotomy, and face-lift scissors; colon, gall duct, multi-purpose, tangential occlusion, peripheral vascu… Read more
Stille AB (STIL) - Net Assets
Latest net assets as of September 2025: Skr692.75 Million SEK
Based on the latest financial reports, Stille AB (STIL) has net assets worth Skr692.75 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.06 Billion) and total liabilities (Skr362.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr692.75 Million |
| % of Total Assets | 65.66% |
| Annual Growth Rate | 20.8% |
| 5-Year Change | 529.83% |
| 10-Year Change | 1327.79% |
| Growth Volatility | 54.42 |
Stille AB - Net Assets Trend (2008–2024)
This chart illustrates how Stille AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Stille AB (2008–2024)
The table below shows the annual net assets of Stille AB from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr699.40 Million | +10.62% |
| 2023-12-31 | Skr632.25 Million | +233.09% |
| 2022-12-31 | Skr189.81 Million | +28.16% |
| 2021-12-31 | Skr148.10 Million | +33.37% |
| 2020-12-31 | Skr111.05 Million | +7.79% |
| 2019-12-31 | Skr103.02 Million | +19.66% |
| 2018-12-31 | Skr86.10 Million | +20.92% |
| 2017-12-31 | Skr71.21 Million | +14.25% |
| 2016-12-31 | Skr62.33 Million | +27.23% |
| 2015-12-31 | Skr48.98 Million | +27.40% |
| 2014-12-31 | Skr38.45 Million | -7.02% |
| 2013-12-31 | Skr41.35 Million | +8.65% |
| 2012-12-31 | Skr38.06 Million | -5.23% |
| 2011-12-31 | Skr40.16 Million | -2.09% |
| 2010-12-31 | Skr41.02 Million | +7.30% |
| 2009-12-31 | Skr38.23 Million | +12.33% |
| 2008-12-31 | Skr34.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Stille AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 22224500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr147.12 Million | 21.04% |
| Common Stock | Skr44.93 Million | 6.42% |
| Other Comprehensive Income | Skr44.86 Million | 6.41% |
| Other Components | Skr462.49 Million | 66.13% |
| Total Equity | Skr699.40 Million | 100.00% |
Stille AB Competitors by Market Cap
The table below lists competitors of Stille AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sotherly Hotels Inc Series B Pref
NASDAQ:SOHOB
|
$82.34 Million |
|
Patriot National Bancorp Inc
NASDAQ:PNBK
|
$82.41 Million |
|
Harsha Engineers International Limited
NSE:HARSHA
|
$82.42 Million |
|
FDENF
PINK:FDENF
|
$82.48 Million |
|
Industri Dan Perdagangan Bintraco Dharma Tbk PT
JK:CARS
|
$82.24 Million |
|
Gan Ltd
NASDAQ:GAN
|
$82.24 Million |
|
Sun Silver Ltd
AU:SS1
|
$82.21 Million |
|
Malaga Financial Corporation
PINK:MLGF
|
$82.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Stille AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 632,254,000 to 699,405,000, a change of 67,151,000 (10.6%).
- Net income of 58,206,000 contributed positively to equity growth.
- Share repurchases of 209,219,000 reduced equity.
- New share issuances of 209,219,000 increased equity.
- Other comprehensive income increased equity by 8,945,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr58.21 Million | +8.32% |
| Share Repurchases | Skr209.22 Million | -29.91% |
| Share Issuances | Skr209.22 Million | +29.91% |
| Other Comprehensive Income | Skr8.95 Million | +1.28% |
| Other Changes | Skr-999.00 | -0.0% |
| Total Change | Skr- | 10.62% |
Book Value vs Market Value Analysis
This analysis compares Stille AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 26.88x to 2.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr7.05 | Skr189.50 | x |
| 2009-12-31 | Skr7.92 | Skr189.50 | x |
| 2010-12-31 | Skr8.50 | Skr189.50 | x |
| 2011-12-31 | Skr8.32 | Skr189.50 | x |
| 2012-12-31 | Skr7.88 | Skr189.50 | x |
| 2013-12-31 | Skr8.57 | Skr189.50 | x |
| 2014-12-31 | Skr7.96 | Skr189.50 | x |
| 2015-12-31 | Skr10.13 | Skr189.50 | x |
| 2016-12-31 | Skr12.92 | Skr189.50 | x |
| 2017-12-31 | Skr14.74 | Skr189.50 | x |
| 2018-12-31 | Skr17.85 | Skr189.50 | x |
| 2019-12-31 | Skr21.34 | Skr189.50 | x |
| 2020-12-31 | Skr22.95 | Skr189.50 | x |
| 2021-12-31 | Skr29.53 | Skr189.50 | x |
| 2022-12-31 | Skr37.86 | Skr189.50 | x |
| 2023-12-31 | Skr126.00 | Skr189.50 | x |
| 2024-12-31 | Skr77.84 | Skr189.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Stille AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.32%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.21%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.43x
- Recent ROE (8.32%) is below the historical average (10.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -5.21% | -1.84% | 1.63x | 1.74x | Skr-5.18 Million |
| 2009 | 13.80% | 5.23% | 1.63x | 1.62x | Skr1.45 Million |
| 2010 | 8.50% | 4.18% | 1.46x | 1.40x | Skr-616.70K |
| 2011 | -2.62% | -1.17% | 1.39x | 1.61x | Skr-5.07 Million |
| 2012 | -5.03% | -2.18% | 1.31x | 1.76x | Skr-5.72 Million |
| 2013 | 7.95% | 3.69% | 1.43x | 1.51x | Skr-847.40K |
| 2014 | 4.92% | 2.32% | 1.46x | 1.45x | Skr-1.95 Million |
| 2015 | 21.43% | 12.57% | 1.20x | 1.42x | Skr5.60 Million |
| 2016 | 26.94% | 17.43% | 1.20x | 1.29x | Skr10.56 Million |
| 2017 | 19.93% | 11.65% | 1.32x | 1.30x | Skr7.07 Million |
| 2018 | 23.44% | 14.86% | 1.18x | 1.34x | Skr11.57 Million |
| 2019 | 22.21% | 14.60% | 0.96x | 1.58x | Skr12.58 Million |
| 2020 | 7.45% | 5.80% | 0.86x | 1.48x | Skr-2.83 Million |
| 2021 | 10.87% | 8.60% | 0.61x | 2.09x | Skr1.29 Million |
| 2022 | 14.40% | 11.09% | 0.72x | 1.80x | Skr8.34 Million |
| 2023 | 4.21% | 9.04% | 0.37x | 1.27x | Skr-36.58 Million |
| 2024 | 8.32% | 10.21% | 0.57x | 1.43x | Skr-11.73 Million |
Industry Comparison
This section compares Stille AB's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $181,120,825
- Average return on equity (ROE) among peers: -25.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Stille AB (STIL) | Skr692.75 Million | -5.21% | 0.52x | $82.32 Million |
| AddLife AB (publ) (ALIF-B) | $1.89 Billion | 27.39% | 1.20x | $1.42 Billion |
| Biotage AB (BIOT) | $476.77 Million | 8.68% | 0.24x | $787.18 Million |
| Bonesupport Holding AB (BONEX) | $124.31 Million | -129.56% | 0.58x | $897.79 Million |
| Dynavox Group (DYVOX) | $210.60 Million | 23.08% | 5.28x | $786.85 Million |
| iZafe Group AB Series B (IZAFE-B) | $9.04 Million | -35.07% | 0.67x | $12.58 Million |
| Ortivus AB ser. A (ORTI-A) | $84.63 Million | -21.84% | 0.94x | $1.20 Million |
| S2Medical AB (S2M) | $25.11 Million | -73.41% | 0.22x | $641.00K |
| Synsam AB (SYNSAM) | $-1.37 Billion | 0.00% | 0.00x | $731.69 Million |